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High-level aminoglycosidesAbstract Background: Tigecycline is a new, semisynthetic glycylcycline. It is active against impor-
tant multidrug resistant pathogens.
Aim: The purpose of this study was to investigate the sensitivity of multidrug-resistant enterococci
to tigecycline, and to test the correlation between the minimal inhibitory concentration (MIC) and
disk diffusion methods.
Materials and methods: The antimicrobial sensitivity of 108 multidrug-resistant isolates, which
included 52 vancomycin-resistant enterococci (VRE) and 56 high-level aminoglycoside-resistant
(HLAR) enterococci, was tested by the E test, broth microdilution test and disk diffusion methods.
Results: All of the isolates were sensitive to tigecycline, as determined by the E test and broth
microdilution test. The MIC 90 value (0.19 lg/mL) of tigecycline for HLAR enterococci was higher
than that for VRE (0.094 lg/mL). When results were evaluated according to species, the MIC
values of tigecycline for Enterococcus faecalis were higher than those for the other species.
Eleven (10.1%) isolates produced false resistance results (zone diameter 615 mm) by the disk dif-
fusion method. These cases were classified as major errors. Eight (7.4%) isolates had intermediate
sensitivity (sensitivity zone of 16 or 17 mm), which were classified as minor errors. The major and
minor error percentages of HLAR enterococci (14.2% major, 10.7% minor error) were higher than
those of VRE (5.7% major, 3.8% minor error). These results indicate that tigecycline is effective
126 L. seri et al.against multidrug-resistant enterococci. The sensitivity of multidrug-resistant enterococci to tigecy-
cline should be investigated by MIC methods. The disk diffusion method causes major errors, espe-
cially for HLAR enterococci.
ª 2015 The Authors. Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1. Introduction
In recent years, the treatment of enterococcal infections has
become more and more difficult because of the increasing
antibiotic resistance of these organisms. Many enterococci
are resistant to vancomycin, ampicillin, and high-level amino-
glycosides, which are the most useful of the traditional antien-
terococcal antibiotics. Linezolid, daptomycin, and tigecycline
are new antibiotics that are used to treat enterococcal infec-
tions. Tigecycline is a tetracycline derivative, and it has been
reported to be effective against vancomycin-resistant entero-
cocci (VRE) and tetracycline-resistant enterococci. However,
the clinical data that are currently available are insufficient.1–5
In this study, we investigated the sensitivity of multidrug-
resistant enterococci to tigecycline. We also examined the cor-
relation between the minimal inhibitory concentration (MIC)
and disk diffusion methods.
2. Materials and methods
This study was performed using 108 strains of enterococci. The
stool samples sent for various tests from patients with diarrhea
or parasitic infection were inoculated on three brain–heart
infusion agar plates containing 6 lg/mL vancomycin or
2000 lg/mL streptomycin or 500 lg/mL gentamicin.6 The
growing colonies were examined by Gram staining and cata-
lase test. Gram positive and catalase negative strains were
tested for their ability to grow on 40% bile-esculin agar
(Difco Laboratories, Detroit, USA) and in 6.5% NaCl broth
(Becton, Dickinson and Company, Sparks, USA). The grow-
ing isolates on esculin agar containing 40% bile and in the
6.5% NaCl broth were identified at the species level using a
RapID (Remel, Lenexa, KA, USA) test kit. All of the strains
were again tested by agar screening method using brain–heart
infusion agar plates containing 6 lg/mL vancomycin or
2000 lg/mL streptomycin or 500 lg/mL gentamicin for van-
comycin and high level aminoglycoside resistance (strepto-
mycin and gentamicin).6
Vancomycin resistant genes of VRE were determined by
polymerase chain reaction (PCR). Bacterial DNA was
extracted from all samples using a NucleoSpin DNA extrac-
tion kit (Macherey–Nagel, Duren, Germany) according to
the manufacturer’s instructions. PCR analysis was performed
as previously described with minor modifications.7
Resistance to tetracycline and ampicillin was tested by the
Bauer–Kirby disk diffusion method. Results were evaluated
according to the CLSI criteria.6
The disk diffusion test for tigecycline was performed and
evaluated according to the recommendations of European
Committee on Antimicrobial Susceptibility Testing
(EUCAST) guidelines (disk content: 15 lg tigecycline; inocula:
McFarland standard 0.5; medium: Mueller–Hinton agar;incubation: 18–20 h at 35 C). The sensitivity zone diameters
of enterococci for tigecycline were published as sensitive
(P18 mm) and resistant (615 mm) by EUCAST guidelines
(2013).8
Tigecycline MIC break points were investigated by the E
test and broth microdilution test.
E tests were performed according to the manufacturer’s
recommendations (AB Biodisk, Solna, Sweden). Inoculum
suspensions with a turbidity equivalent to the 0.5 McFarland
standard were prepared. The suspension was spread evenly
onto a Muller Hinton agar plate. The E test tigecycline gradi-
ent strip was placed on the agar surface, and the plate was
incubated at 35 C for 18–20 h.
The broth microdilution test was performed according to
CLSI guidelines. Mueller–Hinton II broth (BBL, Becton
Dickenson, Sparks, MD) was freshly prepared and used
within 24 h. Microplates (96 wells) containing serial dilu-
tions of tigecycline (Wyeth Research, Pearl River, NY)
(1 lg/ml, 0.5 lg/ml, 0.125 lg/ml, 0.0625 lg/ml, 0,0312 lg/ml,
0.0156 lg/ml) were prepared and each well was inoculated with
test organisms to yield the appropriate density (105 CFU/ml)
in 100 ll Mueller–Hinton broth (MHB) and plates were
incubated for 24 h at 35 C. The MIC was determined as well
with the lowest drug concentration at which there was no
visible growth.9
Enterococcus faecalis ATCC 29212 and E. faecalis ATCC
51299 were used for the quality control of susceptibility tests
and PCR.3. Results
Fifty-two of the isolates were VRE carrying the vanA, vanC1,
or vanC2–3 gene. Fifty-six isolates were high-level aminoglycoside-
resistant (HLAR) enterococci. Forty-six of the HLAR enterococci
isolates were resistant only to streptomycin, seven were resistant
only to gentamicin, and three were resistant to both gentamicin
and streptomycin. The species of the isolates were as follows: 11
Enterococcus gallinarum, 26 Enterococcus casseliflavus, 40
E. faecalis, 29 Enterococcus faecium, 1 Enterococcus durans, and
1 Enterococcus avium. VRE included 9 E. casseliflavus, 11
E. faecalis, 23 E. faecium, 8 E. gallinarum, and 1 E. durans.
HLAR enterococci included 17 E. casseliflavus, 29 E. faecalis, 6
E. faecium, 3 E. gallinarum, and 1 E. avium.
The results of E test were consistent with broth microdilu-
tion tests. All of the isolates were sensitive to tigecycline
according to MIC8–11 and the MIC values ranged from 0.023
to 0.125 lg/mL. The MIC 50 and MIC 90 values were 0.064
and 0.125 lg/mL, respectively. The MIC range for VRE was
from 0.023 to 0.19 lg/mL. The MIC 50 and MIC 90 values
were 0.064 and 0.094 lg/mL, respectively. The MIC range
for HLAR enterococci was from 0.023 to 0.125 lg/mL, and
the MIC 50 and MIC 90 values were 0.094 and 0.19 lg/mL,
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HLAR enterococci than for VRE. The MIC 50 and MIC 90
values of tigecycline are shown in Table 1. The MIC values
for E. faecalis were higher than those for the other species.
The MIC 50 and MIC 90 values for E. faecalis were 0.094
and 0.19 lg/mL, respectively.
All isolates had multiple resistances. Sixty-nine percent of
them were sensitive to ampicillin. The sensitivity rates to tetra-
cycline were low (20%). The antimicrobial sensitivities of the
enterococci are listed in Table 2.
Although all of the isolates were sensitive to tigecycline
according to MIC, the sensitivity zones of 19 (17.5%) isolates
were less than 18 mm according to the disk diffusion method.
The sensitivity zone diameters of enterococci for tigecycline
were published as sensitive (P18 mm) and resistant
(615 mm) by EUCAST guidelines (2013).8 Eleven (10.1%) of
these 19 isolates produced false resistance results (sensitivity
zone diameters 615 mm) by the disk diffusion method.
These cases were classified as major errors. The remaining
eight (7.4%) isolates had intermediate sensitivity (sensitivity
zone diameter of 16 or 17 mm), which were classified as minor
errors. The major and minor error percentages of HLAR ente-
rococci were higher than those of VRE (HLAR, 14.2% major
errors and 10.7% minor errors; VRE, 5.7% major errors and
3.8% minor errors).
When evaluated on a species basis, E. faecalis, E. cas-
seliflavus, E. faecium, and E. gallinarum had 15%, 7.6%,
6.8%, and 9% major errors, respectively. The major and
minor errors of isolates are listed in Table 3.Table 1 Minimum inhibitory concentration (MIC) values of tigecy
Bacteria MIC ra
High-level aminoglycoside-resistant E. casseliflavus 0.032–0
Vancomycin resistance E. casseliflavus 0.023–0
All of E. casseliflavus 0.023–0
High-level aminoglycoside-resistant E faecalis 0.023–0
Vancomycin resistance E. faecalis 0.023–0
All of E. faecalis 0.023–0
High-level aminoglycoside-resistant E. faecium 0.032–0
Vancomycin resistance E. faecium 0.023–0
All of E. faecium 0.023–0
All of E. gallinarum 0.032–0
All of vancomycin-resistant enterococci 0.023–0
All of high-level aminoglycoside-resistant enterococci 0.023–0
All of l isolates 0.023–0
Table 2 Antibiotic susceptibility of enterococci.
Bacteria (n) Antimicrobial drugs n (%)
Tetracycline n (%) Vancomycin
E. gallinarum (11) 3(27) 3(27)
E. casseliflavus (26) 6(23) 12(46)
E. faecalis (40) 6(15) 27(68)
E. faecium (29) 6(21) 3(10)
E. avium (1) 0 1
E. durans (1) 1 0
All of l isolates 22(20) 46(43)4. Discussion
Tigecycline is active against a broad range of bacterial infec-
tions caused by important multidrug-resistant pathogens. It
is a semisynthetic analog of tetracycline, and is effective
against tetracycline-resistant enterococci. The two main mech-
anisms of bacterial resistance to tetracycline are active efflux of
drugs (TetA-E, TetK) from inside the bacterial cell, and ribo-
somal protection (TetO, TetM). The N-alkyl glycylamido side
chain at the carbon-9 position of tigecycline provides some
biological advantages that differ from those of tetracycline.
This side chain increases the lipid solubility of the drug and
creates steric hindrance, which prevents tigecycline from cellu-
lar export by membrane-bound efflux proteins. Furthermore,
the affinity to the binding site on the ribosome is increased.
Tigecycline binds to ribosomes five times stronger than tetracy-
cline. Consequently, tigecycline overcomes tetracycline resis-
tance mechanisms.12 In this study, 80% of isolates were
resistant to tetracycline. Tigecycline was found to be effective
against all of the tetracycline-resistant enterococci.
There are several reports about the activity of tigecycline
against VRE. However, we were unable to find a published
report about its activity against HLAR enterococci. We stud-
ied the effect of tigecycline on VRE and HLAR enterococci in
this study. Thus, to the best of our knowledge, this is the first
study to investigate the effects of tigecycline against HLAR
enterococci.
In almost all previous studies, VRE isolates were sensitive
to tigecycline or their resistance rates for tigecycline were verycline for enterococci.






















Table 3 Error rates of the disk diffusion method according to species.
Bacterial features (n) Major error n (%) Minor error n (%) Total error n (%)
Vancomycin-resistant E. casseliflavus (9)a 1 0 1
Vancomycin-resistant E. faecalis (11) 0 1(0.9) 1(0.9)
Vancomycin-resistant E. faecium (23) 1(4.3) 1(4.3) 2(8.6)
Vancomycin-resistant E. gallinarum (8)a 1(12.5) 0 1(12.5)
Vancomycin-resistant E. durans (1) 0 0 0
Vancomycin-resistant Enterococci (52) 3(5.7) 2(3.8) 5(9.6)
High-level aminoglycoside-resistant E. casseliflavus (17) 1(5.8) 2(11.7) 3(17.6)
High-level aminoglycoside-resistant E. faecalis (29) 6(20.6) 4(13.7) 10(34.4)
High-level aminoglycoside-resistant E. faecium (6)a 1 0 1
High-level aminoglycoside-resistant E. gallinarum (3)a 0 0 0
High-level aminoglycoside-resistant E. avium (1) 0 0 0
High-level aminoglycoside-resistant enterococci (56) 8(14.2) 6(10.7) 14(25)
All of l isolates (108) 11(10.1) 8(7.4) 19(17.5)
a Percentage was not entered because of the smallness of the number.
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to 0.25 lg/mL.2,4,5,13,14 The results of this study confirmed
the previous results related to VRE. All of our VRE isolates
were sensitive to tigecycline, and the MIC 90 value was
0.094 lg/mL.
We observed that the MIC 90 value for HLAR entero-
cocci (0.19 lg/mL) was higher than that for VRE
(0.094 lg/mL). In addition, the MIC 90 value was higher
for HLAR E. faecalis than for VR E. faecalis. The opposite
was true for E. faecium (see Table 1). Unfortunately, the low
number of HLAR E. faecium isolates (only 6 isolates) pre-
cluded any interpretation.
The discordance between the disk method and MIC break
points has been reported in some previous studies. Hope
et al. reported that 5% (major error) of sensitive enterococci
by the agar dilution method were resistant by the disk diffu-
sion method.15 We found a very high major error rate
(10.1%) between the MIC and disk diffusion methods.
In the study by Liu et al., the major error, minor error, and
total error for tigecycline in VRE were reported as 2.6%,
1.1%, and 4%, respectively.16 We observed major and minor
error rates of 5.7% and 3.8%, respectively, for our VRE iso-
lates. The major and minor error percentages of the HLAR
enterococci (14.2% and 10.7%, respectively) were much higher
than those of VRE. The major error rate peaked for HLAR E.
faecalis (20.6%). Acceptable inter-method error rates are 3%
for major error and 10% for minor error.17 Major error per-
centages were higher than acceptable in both our study and
the study by Hope et al.15
These results indicate that tigecycline is effective against
multidrug-resistant enterococci. The sensitivity of multidrug-
resistant enterococci to tigecycline should be investigated by
MIC methods. The disk diffusion method results in major
errors, especially for multidrug-resistant HLAR enterococci.
Conflict of interest
No conflict of interest was declared by the authors.
Acknowledgment
This study was supported by Kırıkkale University Scientific
Research Unit.References
1. Arias CA, Contreras GA, Murray BE. Management of multidrug-
resistant enterococcal infections. Clin Microbiol Infect
2010;16:555–62.
2. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the
glycylcycline tigecycline (GAR-936) against 1,924 recent European
Clinical Bacterial Isolates.AntimicrobAgentsChemother 2003;47:400–4.
3. Bourdon N, Fines-Guyon M, Thiolet JM, Maugat S, Coignard B,
Leclercq R, et al. Changing trends in vancomycin-resistant
enterococci in French hospitals, 2001–08. J Antimicrob
Chemother 2011;66:713–21.
4. Zhao CL, Sun H, Wang H, Liu Y, Hu B, Yu Y, et al.
Antimicrobial surveillance antimicrobial resistance trends among
5608 clinical gram-positive isolates in China: results from the
gram-positive cocci resistance surveillance program (2005–2010).
Diagn Microbiol Infect Dis 2012;73(2):174–81.
5. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infec Dis
2006;43:518–24.
6. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory
Standards Institute. Twenty-Second Informational Supplement.
vol. 32, no. 3; 2012.
7. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide
resistance genotypes and identification to the species level of clinically
relevant enterococci by PCR. J Clin Microbiol 1995;33:24–7.
8. European committee on antimicrobial susceptibility testing.
(EUCAST) Breakpoint tables for interpretation of MIC’s and
zone diameters. version 3.1 valid from 2013-02-11.
9. CLSI document M07-A9. Wayne, PA: Clinical and Laboratory
Standards Institute. Twenty-Second Informational Supplement.
vol. 32, no. 2; 2012.
10. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/
021821s026s031lbl.pdf.
11. Kronvall G, Karlsson I, Walder M, Sörberg M, Nilsson LE.
Epidemiological MIC cut-off values for tigecycline calculated from
Etest MIC valuesusing normalized resistance interpretation. J
Antimicrob Chemother 2006;57(3):498–505.
12. Seputiene V, Povilonis J, Armalyte J, Suziedelis K, Pavilonis A,
Suziedeliene E. Tigecycline – how powerful is it in the fight against
antibiotic-resistant bacteria?Medicina (Kaunas) 2010;46(4):240–8.
13. Pankey GA, Ashcraft DS. In vitro antibacterial activity of
tigecycline against resistant gram-negative bacilli and enterococci
by time-kill assay. Diagn Microbiol Infect Dis 2009;64(3):300–4.
14. Chen YH, Lu PL, Huang CH, Liao CH, Lu CT, Chuang YC,
et al. Trends in the susceptibility of clinically important resistant
bacteria to tigecycline: results from the tigecycline in vitro
surveillance in Taiwan study, 2006 to 2010. Antimicrob Agent
Chemother 2012;56(3):1452–7.
Problematic disk break points of tigecycline against enterococci 12915. Hope R, Mushtaq S, James D, Pllana T, Warner M, Livermore
DM. Tigecycline susceptibility testing group. Tigecycline activity:
low resistance rates but problematic disc breakpoints revealed by a
multicentre sentinel survey in the UK. J Antimicrob Chemother
2010;65:2602–9.
16. Liu JW, Ko WC, Huang CH, Liao CH, Lu CT, Chuang YC, et al.
Agreement assessment of tigecycline susceptibilities determined by
the disk diffusion and broth micro dilution methods amongcommonly encountered resistant bacterial isolates: results from the
Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to
2010. Antimicrob Agents Chemother 2012;56(3):1414–7.
17. Clinical and Laboratory Standards Institute. Development of
in vitro susceptibility testing criteria and quality control param-
eters; approved guideline, 2nd ed. NCCLS document M23–A2.
NCCLS, Wayne, Pa; 2001.
